Castle Biosciences, Inc. (CSTL)

Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investors

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider Selling

Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of Stock

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Castle Biosciences to Open New Laboratory Facility in Scottsdale

New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

JAAD Publication Shows Improved Performance of DecisionDx®-SCC

SciBase receives additional order from Castle Biosciences, advancing the collaboration

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences Approved for Dual Listing on Nasdaq Texas

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Castle Biosciences Q2 Earnings Call Highlights